COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Issues EUA for First-Ever Direct-to-Consumer COVID-19 Test, Moving COVID-19 Further From Clinical Laboratories

Models forming toward at-home testing for COVID-19.
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

New EUA advances patients’ autonomy in deciding to seek a COVID-19 test, but may impact the role of clinical laboratories

Since the early days of the COVID-19 pandemic, it has been the goal of COVID-19 test developers to offer easily accessible testing that could be performed in the home environment. There are many ways that this goal has been realized since the pandemic has started. Mobile or at-home COVID-19 testing done by clinical laboratory professionals initially emerged as a potential solution. (See Northwell Health Labs Uses Mobile Phlebotomy App to Better Serve Patients, Increase Test Volume and Revenue During COVID-19 Outbreak.) As testing technology rapidly developed, a variety of emergency use authorizations (EUAs) were soon issued to permit at-home specimen collection.

More recently, advances in at-home testing included the issuance of an EUA for the first fully at-home COVID-19 diagnostic test. (See At-Home COVID-19 Testing Finally Arrives: Laboratory Expert Weighs in on the Implications for Clinical Laboratories.) This development made way for the first COVID-19 test to be performed without needing a CLIA-certified clinical laboratory. The test from Lucira Health, which requires a prescription, is expected to impact the COVID-19 testing market when it becomes nationally available in spring 2021.

Now, Another Regulatory Event May Significantly Impact COVID-19 Test Volumes

Now, a new regulatory event moves COVID-19 testing even further away from clinical laboratories and makes at-home COVID-19 testing easier for consumers. On Dec. 9, 2020, the US Food and Drug Administration (FDA) issued an EUA for LabCorp’s Pixel COVID-19 Test Home Collection Kitallowing this collection kit to be sold direct-to-consumer (DTC)—without requiring a prescription. This kit consists of a nasal swab that can be collected at home and sent to LabCorp for PCR analysis. The only restriction on this kit is that it must only be used by those who are 18 years or older.

Brian Caveney LabCorp COVID-19 test impact on clinical laboratories
Brian Caveney, MD, Chief Medical Officer and President of LabCorp Diagnostics

“With the first over-the-counter at-home collection kit ever authorized by the FDA for COVID-19, we are empowering people to learn about their health and make confident decisions,” Brian Caveney, MD, Chief Medical Officer and President of LabCorp Diagnostics said in a recent statement. “With this authorization, we can help more people get tested, reduce the spread of the virus and improve the health of our communities.”

“While many home collection kits can be prescribed with a simple online questionnaire, this newly authorized direct-to-consumer collection kit removes that step from the process,” says Jeff Shuren, MD, JD, Director of the FDA’s Center for Devices and Radiological Health, “allowing anyone to collect their sample and send it to the lab for processing.”

Implications of First Nonprescription DTC COVID-19 Test

While the availability of a nonprescription, at-home COVID-19 test collection kit will certainly increase the ease with which testing can be obtained, this new EUA seems to benefit LabCorp exclusively. This has the potential to lead to less use of other at-home collection kits and shift the at-home collection COVID-19 testing market away from most clinical laboratories and toward LabCorp.

The FDA’s recent decision to focus on increasing COVID-19 testing and accessibility may be part of a broader trend. If the existing individual authorization for fully at-home testing and nonprescription testing were to be combined into a single test, then patients would be able to perform their own tests completely free of any contact with the medical profession. While this would increase the accessibility of COVID-19 for the public, it could have implications both for the follow-up care that patients would be likely to seek and for the role of clinical laboratories in the COVID-19 pandemic.

Caleb Williams

—By Caleb Williams, Editor, COVID-19 STAT

Related Resources:

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group